Skip to main content
Azka Ali, MD, Oncology, Cleveland, OH

Azka Ali MD MD (She/Her)

Breast Cancer, Hematologic Oncology


Associate Staff Breast Medical Oncology Cleveland Clinic Taussig Cancer Institute

Join to View Full Profile
  • 9500 Euclid AvenueCleveland, OH 44195

  • Phone+1 216-444-5660

Dr. Ali is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Florida
    University of FloridaFellowship, Hematology and Medical Oncology, 2019 - 2022
  • University of Florida
    University of FloridaChief Residency, Internal Medicine, 2018 - 2019
  • University of Florida
    University of FloridaResidency, Internal Medicine, 2015 - 2018
  • Medical University of South Carolina
    Medical University of South CarolinaClass of 2015
  • University of South Carolina
    University of South Carolina BS, Biology, Summa Cum Laude with Honors, 2007 - 2011

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2022 - 2026
  • FL State Medical License
    FL State Medical License 2018 - 2024
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • What Oncologists Should Consider About ESR1 Mutations in Breast Cancer
    What Oncologists Should Consider About ESR1 Mutations in Breast CancerApril 1st, 2025
  • Improving Efficacy, Minimizing Toxicity in Chemotherapy for Breast Cancer
    Improving Efficacy, Minimizing Toxicity in Chemotherapy for Breast CancerFebruary 7th, 2025
  • FDA Approvals Change Practice for Metastatic Breast Cancer with PIK3CA Mutations
    FDA Approvals Change Practice for Metastatic Breast Cancer with PIK3CA MutationsJanuary 8th, 2025
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: